IngentaConnect A randomized double-blind placebo-controlled trial of Lactobacill...

Authors: GAWROŃSKA, A.¹; DZIECHCIARZ, P.¹; HORVATH, A.²; SZAJEWSKA, H.²

Source: Alimentary Pharmacology & Therapeutics, Volume 25, Number 2, January 2007 , pp. 177-184(8)

Abstract:

Summary Background

Functional abdominal pain disorders (FAPD) are common in school-aged children; however, there is no reliable treatment. Aim

To determine the efficacy of Lactobacillus rhamnosus GG (LGG) for treating FAPD in children. Methods

A total of 104 children who fulfilled the Rome II criteria for functional dyspepsia (FD), or irritable bowel syndrome (IBS), or functional abdominal pain (FAP) were enrolled in a double-blind, randomized controlled trial in which they received LGG (n = 52), or placebo (n = 52) for 4 weeks. Results

For the overall study population, those in the LGG group were more likely to have treatment success (no pain) than those in the placebo group (25% vs. 9.6%, relative benefit (RB) 2.6, 95% confidence interval (CI): 1.05-6.6, number needed to treat (NNT) 7, 95% CI: 4-123). For children with IBS (n = 37), those in the LGG group were more likely to have treatment success than those in the placebo group (33% vs. 5%, RB 6.3, 95% CI: 1.2-38, NNT 4, 95% CI: 2-36) and reduced frequency of pain (P = 0.02), but not pain severity (P = 0.10). For the FD group (n = 20) and FAP group (n = 47), no differences were found. Conclusion

The LGG appears to moderately increase treatment success, particularly among children with IBS.

Document Type: Research article

DOI: 10.1111/j.1365-2036.2006.03175.x

Affiliations: 1: Department of Paediatric Gastroenterology and Nutrition, The Medical University of Warsaw, Warsaw 2: The Second Department of Paediatrics (II Katedra Pediatrii), The Medical University of Warsaw, Warsaw, Poland

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.16 plus tax Refund Policy

A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children